Company release
____________________________________________
Person subject to the notification requirement
Position: Chief Executive Officer
Issuer:
LEI: 743700W4CQVYAT3WKK38
Notification type: INITIAL NOTIFICATION
Reference number: 33224/5/8
____________________________________________
Transaction date: 2023-06-09
Outside a trading venue
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Nature of transaction: ACCEPTANCE OF A STOCK OPTION
Transaction details
(1): Volume: 165000 Unit price:
Aggregated transactions (1):
Volume: 165000 Volume weighted average price:
____________________________________________
Further information:
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email:ir@herantis.com
Certified Advisor:
Company website: www.herantis.com
Distribution:
Main media
www.herantis.com
https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-oyj--managers--transactions---antti-vuolanto,c3784057
https://mb.cision.com/Main/18884/3784057/2118335.pdf
(c) 2023 Cision. All rights reserved., source